Antares Pharma Inc Expected to Earn Q1 2019 Earnings of $0.01 Per Share (ATRS)
Antares Pharma Inc (NASDAQ:ATRS) – Analysts at Piper Jaffray Companies issued their Q1 2019 earnings per share estimates for Antares Pharma in a report released on Thursday, August 16th. Piper Jaffray Companies analyst D. Amsellem expects that the specialty pharmaceutical company will earn $0.01 per share for the quarter. Piper Jaffray Companies has a “Buy” rating and a $4.00 price target on the stock. Piper Jaffray Companies also issued estimates for Antares Pharma’s Q3 2019 earnings at $0.05 EPS, FY2020 earnings at $0.30 EPS and FY2021 earnings at $0.36 EPS.
A number of other brokerages have also recently commented on ATRS. HC Wainwright set a $5.00 price objective on Antares Pharma and gave the stock a “buy” rating in a research note on Friday. BidaskClub raised Antares Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, August 14th. Finally, ValuEngine raised Antares Pharma from a “hold” rating to a “buy” rating in a research note on Wednesday, August 8th.
Antares Pharma (NASDAQ:ATRS) last released its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.01). The firm had revenue of $14.16 million during the quarter, compared to analyst estimates of $13.70 million. Antares Pharma had a negative net margin of 35.53% and a negative return on equity of 64.96%.
Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. grew its stake in shares of Antares Pharma by 7.3% during the second quarter. BlackRock Inc. now owns 9,805,325 shares of the specialty pharmaceutical company’s stock worth $25,298,000 after purchasing an additional 664,681 shares during the period. FMR LLC grew its stake in shares of Antares Pharma by 38.8% during the second quarter. FMR LLC now owns 3,640,800 shares of the specialty pharmaceutical company’s stock worth $9,393,000 after purchasing an additional 1,018,300 shares during the period. Mycio Wealth Partners LLC acquired a new stake in shares of Antares Pharma during the second quarter worth $6,278,000. Wells Fargo & Company MN grew its stake in shares of Antares Pharma by 21.5% during the first quarter. Wells Fargo & Company MN now owns 1,933,469 shares of the specialty pharmaceutical company’s stock worth $4,253,000 after purchasing an additional 342,062 shares during the period. Finally, JW Asset Management LLC grew its stake in Antares Pharma by 2.8% in the second quarter. JW Asset Management LLC now owns 1,820,524 shares of the specialty pharmaceutical company’s stock valued at $4,697,000 after acquiring an additional 50,000 shares during the period. 38.31% of the stock is owned by institutional investors and hedge funds.
In related news, Director Jacques Gonella sold 49,507 shares of Antares Pharma stock in a transaction on Monday, August 13th. The stock was sold at an average price of $3.09, for a total transaction of $152,976.63. Following the completion of the sale, the director now directly owns 9,985,848 shares of the company’s stock, valued at $30,856,270.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders have sold 1,236,115 shares of company stock valued at $3,365,861. 12.20% of the stock is owned by insiders.
Antares Pharma Company Profile
Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Read More: How Do You Make Money With Penny Stocks?
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.